Phase II Study of Imatinib Mesylate (Gleevec) in Relapsed or Refractory WM
Sponsor: Novartis, Inc.
Institution: Dana-Farber Cancer Institute
Physician: Steven P. Treon, MD, MA, PhD
This study will assess the activity of imatinib mesylate in patients with WM. The study is for patients who have had treatment in the past that was not effective or whose disease has returned after treatment. Patients will receive four weeks of imatinib; those patients who have no disease progression or adverse side effects during initial treatment will continue at a higher dose for up to two years. Imatinib has been approved by the FDA for use in other cancers. To test efficacy, we will do blood tests, bone marrow biopsies, and chest and abdominal CAT scans. We will also conduct corollary studies to find blood markers that might predict how a WM patient will respond to imatinib and better understand how the drug works in WM cells.